Shibata Norihito, Jishage Kou-ichi, Arita Makoto, Watanabe Miho, Kawase Yosuke, Nishikawa Kiyotaka, Natori Yasuhiro, Inoue Hiroyasu, Shimano Hitoshi, Yamada Nobuhiro, Tsujimoto Masafumi, Arai Hiroyuki
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
FASEB J. 2006 Dec;20(14):2642-4. doi: 10.1096/fj.06-6368fje. Epub 2006 Oct 31.
Supernatant protein factor (SPF) is a novel cholesterol biosynthesis-accelerating protein expressed in liver and small intestine. Here, we report on the physiological role of SPF by using Spf-deficient mice. Although plasma cholesterol levels were similar in chow-fed Spf-/- and wild-type (WT) mice, fasting significantly decreased plasma cholesterol levels in Spf-/- mice but not in WT mice. While fasting reduced hepatic cholesterol synthesis rate in WT mice, a more pronounced reduction was observed in Spf-/- mice. The expression of cholesterogenic enzymes was dramatically suppressed by fasting both in WT and Spf-/- mice. In contrast, hepatic SPF expression of WT mice was up-regulated by fasting in peroxisome proliferator-activated receptor alpha (PPAR-alpha)-dependent manner. These results indicate that in WT mice, the decrease of hepatic cholesterol synthesis under fasting conditions is at least in part compensated by SPF up-regulation. Fibrates, which function as a PPAR-alpha agonist and are widely used as hypotriglycemic drugs, reduced hepatic cholesterol synthesis and plasma cholesterol levels by approximately one-half in Spf-/- mice but not in WT mice. These findings suggest that co-administration of fibrates and an SPF inhibitor may reduce not only plasma triglyceride but also cholesterol levels, indicating that SPF is a promising hypocholesterolemic drug target.
上清蛋白因子(SPF)是一种在肝脏和小肠中表达的新型胆固醇生物合成加速蛋白。在此,我们通过使用Spf基因缺陷小鼠来报告SPF的生理作用。尽管在喂食普通饲料的Spf基因敲除小鼠和野生型(WT)小鼠中血浆胆固醇水平相似,但禁食显著降低了Spf基因敲除小鼠的血浆胆固醇水平,而WT小鼠则没有。禁食时,WT小鼠肝脏胆固醇合成速率降低,而在Spf基因敲除小鼠中观察到更明显的降低。在WT和Spf基因敲除小鼠中,禁食均显著抑制了胆固醇生成酶的表达。相反,WT小鼠肝脏SPF的表达在禁食时以过氧化物酶体增殖物激活受体α(PPAR-α)依赖的方式上调。这些结果表明,在WT小鼠中,禁食条件下肝脏胆固醇合成的减少至少部分由SPF上调所补偿。贝特类药物作为PPAR-α激动剂,被广泛用作降血糖药物,在Spf基因敲除小鼠中可使肝脏胆固醇合成和血浆胆固醇水平降低约一半,而在WT小鼠中则无此作用。这些发现表明,联合使用贝特类药物和SPF抑制剂不仅可以降低血浆甘油三酯水平,还可以降低胆固醇水平,这表明SPF是一个有前景的降胆固醇药物靶点。